Resubmission of NDA On Track for Early Q2 24— Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r
Iterum Therapeutics Reports Second Quarter 2023 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Registration Trial for uUTI Ongoing and On Track Cash Runway until Mid-2024 DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage